Skip to content

Home
Insights
Brochures
Careers
About us
News

Home
Insights
Brochures
Careers
About us
News

Pharma News

Highlights from the Week of 01st June 2026 - 08th June 2026 ( EU, Approval ) EC grants approval to Sanofi's SARCLISA SC in combination with standard-of-care regimens for the treatment of patients with multiple myeloma ( FDA, Orphan Drug, Fast Track ) TearSolutions' LACRIPEP received Orphan Drug and Fast Track designations from the FDA to treat neurotrophic keratitis ( FDA, Fast Track ) FDA grants Fast Track designation to Merakris Therapeutics' MTX-001 that treats venous leg ulcers ( FDA, Fast Track ) FDA provides Fast Track designation to Verastem Oncology's VS-7375 for the treatment of adult patients with KRAS G12D-mutated unresectable locally advanced or metastatic NSCLC Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 01st June – 08th June in the world of pharma and healthcare!

June 9, 2026

Highlights from the week of 25th May - 01st June AbbVie ( FDA, Approval ) AbbVie's DECNUPAZ gains FDA approval to treat BPDCN, a hematologic malignancy with limited treatment options AstraZeneca ( FDA, Approval ) FDA gives approval to AstraZeneca's IMFINZI in combination with BCG induction and maintenance therapy for the treatment of adult patients with BCG-naïve, high-risk NMIBC Shionogi ( FDA, Approval ) Shionogi's XOCOVA receives FDA approval for post-exposure prophylaxis of COVID-19 in adults and adolescents 12 years and older Mannkind ( FDA, Approval ) MannKind's AFREZZA inhalation powder is now FDA approved for use in children and adolescents aged 6 years and older with type 1 and 2 diabetes All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 25th May – 01st June in the world of pharma and healthcare!

June 1, 2026

Highlights from the Week of 18th May 2026 - 25th May 2026 ( FDA, Approval ) AstraZeneca and Daiichi Sankyo gets FDA approval for its DATROWAY to treat adults with unresectable or metastatic TNBC ( FDA, Approval ) FDA approves AstraZeneca's BAXFENDY, an aldosterone synthase inhibitor, for the treatment of hypertension in combination with other antihypertensives ( FDA, Approval ) Bio-Thera and Accord BioPharma gets FDA approval for IMMGOLIS and IMMGOLIS INTRI, a biosimilar for the treatment of adults with moderately to severely active rheumatoid arthritis and ulcerative colitis ( CHMP, Positive Opinion ) Merck gets positive CHMP opinion for KEYTRUDA in combination with PADCEV as neoadjuvant treatment and as adjuvant treatment post radical cystectomy for adults with resectable MIBC Pg 1/3 All logos and trademarks remain the intellectual properties of their respective owners

Highlights from the Week of 18th May – 25th May in the world of pharma and healthcare!

May 26, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Investor calendar

Q1 2026 Earnings Call Apr 28,2026 To Apr 30,2026 April 28 April 29 April 30 All logos and trademarks remain the intellectual properties of their respective owners

Attention stay up to date with the latest investor calls by checking out our calendar for the week of April 28,2026 To April 30,2026

April 28, 2026

Q1 2026 earning call April 23,2026 To April 24,2026 April 23 April 24 All logos and trademarks remain the intellectual properties of their respective owners

Attention Stay up to date with the latest investor calls by checking out our calendar for the week of April 23,2026 To April 24,2026

April 20, 2026

INVESTOR CALENDER OF THE WEEK April 15,2026 To April 16,2026 Conference, HSBC Global Investment Summit, Hong Kong Needham 25th Annual Healthcare Conference Apr 15 Apr 15 Q1 2026 Earning Call Apr 16 All logos and trademarks remain the intellectual properties of their respective owners

Attention ⏰ Stay up to date with the latest investor calls by checking out our calendar for the week of April 15,2026 To April 16,2026

April 13, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

Healthcare Insights

INFLAMMATORY BOWEL DISE SE IBD is an umbrella term for a group of conditions that cause swelling and inflammation of the tissues in the digestive tract Global Prevalence and Incidence Country-wise affected population Prevalence 2.4-3.1M 229.7 per 100,000 2.5-3 M Incidence Low Low with increase 0.18 M High TYPES OF IBD Crohn's disease Ulcerative colitis Crohn's disease (CD): It can affect any part of the digestive tract from mouth to anus and causes deep, tissue-layer inflammation Ulcerative colitis (UC): It affects only the colon and rectum's inner lining, causing inflammation and ulcers DIAGNOSIS Blood Test Stool Test Upper Endoscopy Colonoscopy Tissue Biopsy Imaging Studies Risk factors Causes of inflammatory Bowel Disease Medium Women face a higher risk of CD; men face a higher risk of UC Smoking affects development and severity of Crohn's Commonly diagnosed between ages 15-35 Luminal Factors Microbiome Intestinal Immune System Alterations Environmental Factor Genetic Predisposition SYMPTOMS Loss of appetite Fatigue Stomach aches and cramps Weight loss Diarrhea Blood in your stool TREATMENT Surgery Bowel resection Top-down approach Nutritional support Probiotics Biologic therapy Adalimumab & Infliximab Immunosuppressants Methotrexate, Azathioprine & Mercaptopurine Corticosteroids Budesonide, Methylprednisolone & Prednisolone 5-ASA | Antibiotics 5 ASA- Mesalamine & Sulfasalazine | Antibiotics- Ciprofloxacin & Metronidazole Step-up approach Vyuhpharma® All Rights Reserved Note: This report is generated based on publicly available data

True workplace inclusivity means supporting employees with chronic, often invisible conditions. Inflammatory Bowel Disease (IBD) affects millions of professionals worldwide, impacting daily life, energy and productivity.This World IBD Day, let’s advocate for understanding, flexible workplaces, and healthcare support. 💼💜

May 19, 2026

High blood pressure isn’t just a clinical issue; it’s a productivity and workplace wellness issue. Given that stress is a major contributor to hypertension, the 2026 theme “Controlling Hypertension Together” hits home for leadership teams everywhere. Let’s foster environments where health is as important as the bottom line. 📈❤️

May 17, 2026

On World Lupus Day, we stand in support of everyone affected by lupus — raising awareness, encouraging early diagnosis, and advocating for better care and research. 💜Together, we can help improve lives through awareness, innovation, and compassion.

May 10, 2026

« Previous Page1 Page2 Page3 Page4 Page5 Next »

The Pharma BI division of

Vyuhgenics Inc.

Henderson, Nevada, USA – 89014

Vyuhpharma ®, All Rights Reserved.

Sitemap

Terms of use

Connect with us

Please fill in the information below, and we'll get back to you.

Full Name

Email Address

Your Company

Contact

Your message